ISA104 / ISA Pharma - LARVOL DELTA

HEB-PEP: Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (clinicaltrials.gov) - P1/2 | N=24 | Active, not recruiting | Sponsor: Erasmus Medical Center | Recruiting ➔ Active, not recruiting | Trial completion date: Nov 2025 ➔ Mar 2027 | Trial primary completion date: Sep 2024 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Hepatitis B • Infectious Disease • Inflammation

HEB-PEP: Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Erasmus Medical Center | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis B • Infectious Disease • Inflammation

HEB-PEP: Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Erasmus Medical Center | Not yet recruiting ➔ Recruiting | Initiation date: May 2023 ➔ Aug 2023

Enrollment open • Trial initiation date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

HEB-PEP: Evaluation of the Novel Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination ISA104 (clinicaltrials.gov) - P1/2 | N=24 | Not yet recruiting | Sponsor: Erasmus Medical Center

New P1/2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation